Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358549 | 0.87 | CYP17A1 (0.70) | CYP17A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL377276 | 0.82 | CYP17A1 (0.63) | CYP17A1CYP2C19SMN1; SMN2CYP3A4CYP19A1 | |
| Ammonia Solution, Strong SCHEMBL5999968 | 0.82 | CYP17A1 (0.61) | CYP17A1KMT2AKDM4ECYP19A1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL5998623 | 0.82 | CYP17A1 (0.61) | CYP17A1MEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL13871997 | 0.81 | CYP17A1 (0.64) | CYP17A1MEN1KMT2AMIFLMNA | |
| Ammonia Solution, Strong SCHEMBL5999908 | 0.79 | CYP17A1 (0.57) | CYP17A1MEN1KMT2AKDM4ECYP1A2 | |
| Ammonia Solution, Strong SCHEMBL5999950 | 0.79 | CYP17A1 (0.57) | CYP17A1KMT2ACYP2C19NPC1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL5999712 | 0.79 | SLC6A3 (0.59) | CYP17A1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10460417 | 0.79 | CYP17A1 (0.61) | CYP17A1MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL24610441 | 0.78 | CYP17A1 (0.60) | CYP17A1KMT2ACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | CYP17A1 4384/4885MEN1 2357/4885KMT2A 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.